Recently, on the occasion of the Fifth China Brand Day, seven national ministries and commissions, including Xinhua News Agency and SASAC News Center, jointly hosted China Brand Value Evaluation Information Release and China Brand Building Summit Forum 2021 in Shanghai. The forum released China Brand Value Evaluation Information 2021. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma") was ranked third in the national ranking of the "Medicine and Health" category with a brand value of RMB 24.634 billion, maintaining a high growth momentum.
Hansoh Pharma highly values brand building, and promotes innovation and development by building a comprehensive brand management system. The company has kept working on organizational building for brand management, developed proper brand expansion and brand protection strategies, and fully leveraged the leading role of brand in operations. Excellent brand management initiatives have strongly enhanced the brand value and won for the company full, authoritative affirmation in multiple dimensions such as quality, technological innovation, market and service, and social responsibility, reflecting the fruitful results achieved by the company in the process of innovation-driven transformation and upgrading.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has been ranked top 30 among Top 100 Companies in China's Pharmaceutical Industry and top 3 among China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years; has won important national honors such as Second Prize of National Science and Technology Progress Award and China Patent Gold Award for many times; and has been recognized as National Technological Innovation Demonstration Enterprise and Grade AAA Credit Enterprise successively.
After more than 20 years of high-intensity R&D investment, Hansoh Pharma has launched four Class 1 innovative drugs, namely Ameile (Almonertinib Mesilate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets), Fulaimei (Polyethylene Glycol Loxenatide Injection) and Mailingda (Morinidazole and Sodium Chloride Injection). The Phase III study of Ameile for first-line treatment of EGFR mutation-positive locally advanced or metastatic NSCLC has reached the primary study endpoint, and the latest study results will be released at ASCO 2021; the Class 1 innovative drug for the treatment of hepatitis B, Hengmu (Tenofovir Amibufenamide Tablets) will soon be approved for marketing, which is worth looking forward to.
In the 14th Five-Year Plan period, Hansoh Pharma will be committed to improving human health through continuous innovation, place focus on the treatment of major diseases in the fields of anti-tumor, central nervous system, anti-infection and diabetes, and strive to meet the unmet medical needs in clinical practice; and will also leverage is own brand influence, give full play to the leading role of brand as an industry giant, create excellence in pharmaceuticals, enhance innovation in China, increase the global visibility of Chinese brands, and help Chinese brands establish global presence.
